Liquidia Says Federal Circuit Affirmed Earlier PTAB Decision To Invalidate All Claims Of United Therapeutics Patent No. 10,716,793 ('793 Patent)
Portfolio Pulse from Benzinga Newsdesk
The Federal Circuit has affirmed an earlier PTAB decision to invalidate all claims of United Therapeutics' patent No. 10,716,793. Liquidia will seek to lift the injunction imposed by the District Court in Delaware and continue pursuing FDA approval for YUTREPIA.
December 20, 2023 | 9:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
United Therapeutics may face a negative short-term impact due to the invalidation of its '793 Patent, which could lead to increased competition for its products.
The invalidation of the '793 Patent represents a loss of exclusivity that could allow competitors like Liquidia to enter the market, potentially affecting United Therapeutics' market share and revenue.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Liquidia may experience a positive short-term impact as the Federal Circuit's decision allows it to pursue FDA approval for YUTREPIA without the legal hurdle of the '793 Patent.
The court's decision directly benefits Liquidia by removing a significant legal barrier, potentially accelerating the approval process for YUTREPIA, which could be a major catalyst for the company's stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90